Skip to main content

Press Releases

Recent Press Releases

Hepion Pharmaceuticals to Present Rencofilstat’s Poly-Indication Potential at the 6th Annual Antifibrotic Drug Development Summit
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
Hepion Pharmaceuticals to Present Two Posters at Upcoming AASLD The Liver Meeting® 2022
Hepion Pharmaceuticals Announces Publication of Phase 2a ‘AMBITION’ Clinical Trial Results
Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat
Hepion Pharmaceuticals to Participate in the ThinkEquity Conference
Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
Upcoming Presentation at Joint Meeting of ISBRA and ESBRA to Highlight Potential of Hepion Pharmaceutical’s Rencofilstat to Treat Alcohol-Related Liver Disease
Hepion Pharmaceuticals Announces Initiation of Dosing in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Hepion Pharmaceuticals Announces Initiation of Phase 2b ‘ASCEND-NASH’ Trial
Hepion Pharmaceuticals Announces Further Adjournment of Annual Meeting of Stockholders
Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders
Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma
Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress™ 2022
Hepion Pharmaceuticals Appoints Accomplished Life Sciences Industry Veteran, Dr. Launa J. Aspeslet, as Chief Operating Officer
Hepion Pharmaceuticals Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting
Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Rencofilstat at 5th Global NASH Congress
Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial
Hepion Pharmaceuticals Appoints World-Renowned Hepatologist, Dr. Eddie C. Cheung, to Lead the Company’s Strategic Medical Affairs in Asia
Hepion Pharmaceuticals to Present at BIO CEO & Investor Conference
Hepion Pharmaceuticals’ Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study
Hepion Pharmaceuticals Announces Death of Director, Thomas Adams
Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431
Hepion Pharmaceuticals Announces Participation in the H.C. Wainwright BioConnect Conference
Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer
Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021
Anti-Cancer Mechanism of Hepion Pharmaceuticals’ CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference
All Endpoints Met in Hepion Pharmaceuticals’ Drug-Drug Interaction Study with CRV431
Additional Data from Hepion Pharmaceuticals’ Phase 2a ‘AMBITION’ Trial Further Strengthens CRV431 Clinical Profile and Paves Way for Initiation of Phase 2b ‘ASCEND-NASH’ Clinical Program
Hepion Pharmaceuticals Schedules Conference Call to Review Data from Phase 2a ‘AMBITION’ Clinical Trial of CRV431 in NASH
Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders
Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a ‘AMBITION’ NASH Trial; All Primary Endpoints Achieved
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting
Hepion Pharmaceuticals to be Added to the Russell Microcap® Index
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a ‘AMBITION’ Clinical Trial of CRV431 for the Treatment of Advanced NASH
Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress
DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical’s Lead Drug, CRV431
Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference
Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at NASH-TAG 2021
Hepion Pharmaceuticals, Inc. Announces Closing of Public Offering
Hepion Pharmaceuticals Announces Pricing of Public Offering
Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
Hepion Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference
Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences
Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a ‘AMBITION’ Clinical Trial for Treatment of Advanced NASH
Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a ‘AMBITION’ Clinical Trial for Treatment of Advanced NASH
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19
Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a ‘AMBITION’ Clinical Trial for NASH
Hepion Pharmaceuticals’ CRV431 Demonstrates Additional Potential Advantage in Liver Disease
Hepion Announces Closing of Public Offering of Common Stock
Hepion Pharmaceuticals Prices Public Offering
Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation of Phase 2a ‘AMBITION’ Clinical Trial for Treatment of Advanced NASH
Hepion Pharmaceuticals to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium
Hepion Pharmaceuticals to Present at The Liver Meeting Digital Experience(TM) 2020
Hepion Pharmaceuticals to Present on Therapeutic Approaches to COVID-19 and NASH at Two Virtual Conferences on October 28 and 29, 2020
Hepion Pharmaceuticals Introduces Proprietary A.I. Platform for Drug Development & Announces Creation of Clinical Pharmacology Analytics Team
Hepion Pharmaceuticals to Present at H.C. Wainwright’s 4th Annual NASH Virtual Investor Conference
Hepion Pharmaceuticals Reports Positive Activity of CRV431 Against Coronavirus SARS-2 in Study Conducted by the National Institute of Allergy and Infectious Diseases
Hepion Pharmaceuticals Completes Final Dosing in Phase 1b Multiple Ascending Dose Study of CRV431
Hepion Pharmaceuticals to Present CRV431 Preclinical Data at the 2020 Digital International Liver Congress(TM)
Hepion Pharmaceuticals Announces Publication of Preclinical Study Evaluating CRV431’s Antiviral Properties
Hepion Pharmaceuticals Announces First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial
Hepion Pharmaceuticals Announces Preclinical Data Supporting Novel Two-Pronged Approach to Treating COVID-19 with CRV431
Hepion Pharmaceuticals Announces Advancement to Final Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Kidney Fibrosis
Hepion Pharmaceuticals Welcomes Industry Veteran and Drug Development Expert, Dr. Peter Wijngaard, to its Board of Directors
Hepion Pharmaceuticals Announces Advancement to Fourth Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
Hepion Pharmaceuticals’ CRV431 the First Cyclophilin Inhibitor to Advance to Phase 2 Trial for NASH Fibrosis
Hepion Pharmaceuticals’ CRV431 Demonstrates Efficacy in Human Idiopathic Pulmonary Fibrosis Translational Research Study
Anti-Fibrotic Activity of Hepion Pharmaceuticals’ CRV431 Shows Potential to Extend to Multiple Organs and Fibrotic Diseases
Hepion Pharmaceuticals Announces Advancement to Third Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
Hepion’s NASH Drug Candidate, CRV431, Demonstrates Superior Antifibrotic Efficacy in Expanded Human Liver Study
Hepion Pharmaceuticals Presents Update on CRV431 Nonclinical Studies at NASH-TAG 2020 Conference
Hepion Pharmaceuticals Announces Publication in Expert Opinion on Investigational Drugs
Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
Hepion Pharmaceuticals to Present Clinical and Scientific Updates at HEP DART 2019
Hepion Pharmaceuticals Announces Canadian Research Team’s Academic Appointments
Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference
Hepion Pharmaceuticals’ CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease
Hepion Pharmaceuticals to Present at The Liver Meeting(R) 2019
Hepion Pharmaceuticals’ CRV431 Reduces Liver Fibrosis in a Western Diet Model of NASH
Hepion Pharmaceuticals to Present on CRV431 at the 3rd Annual NASH Summit
Hepion Pharmaceuticals Announces Publication of Data Highlighting CRV431’s Potential as a Treatment for Chronic Liver Diseases
World-Renowned Liver Disease Expert, Dr. Stephen Harrison, Joins Hepion Pharmaceuticals as Consultant Medical Director
Hepion Pharmaceuticals Strengthens Management Team with Three Key Promotions
Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference
Hepion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431
Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board
Hepion Pharmaceuticals Announces Research Partnership with Applied Pharmaceutical Innovation, Faculty of Pharmacy & Pharmaceutical Sciences at University of Alberta